Published: Dec 24, 2020
  
 
     
 
Keywords:
Attention deficit/hyperactivity disorder complex ADHD coexisting conditions
  
     
 
   
 
 
 
 
 
 
 
 
 
 
 

 

 
   
 
 
 
    Language
  
      English  
      ภาษาไทย  
 
 
    Information
  
      For Readers  
      For Authors  
      For Librarians  
 
 
    Home ThaiJo
  
   
 
 
 
    Manual
  
      For Author  
      For Reviewer  
 
 
   Author Guidelines
  
      Author Guidelines  
       
 
 
    เว็บไซต์
  
      โรงพยาบาล
    เจริญกรุงประชารักษ์		  
      www.ckphosp.go.th  
 
 

 

 
     
    Home / Archives / Vol. 16 No. 2 (2020): July - December / Research Article  
 
   
 

Attention deficit/hyperactivity disorder in children and adolescence
   
 
   
   
     
 
กิตติพงศ์ มาศเกษม
กลุ่มงานกุมารเวชกรรม โรงพยาบาลเจริญกรุงประชารักษ์

Abstract

Introduction: Attention Deficit/Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder presented in childhood and adolescent period. For those suffering from this disorder, the individually specialized care is required and crucial as their quality of lives can be inevitably affected from childhood to adulthood. Knowledge of ADHD and its effective care are therefore vital for the team providing multidisciplinary care including pediatrician, child psychiatrist, pediatric nurse and teacher.


Objective: This article aims to review the regularly updated information about ADHD in terms of epidemiology, causes and management for maximizing the quality of life of children and adolescence with ADHD.


Methodology: Review article


Results: ADHD is the neurodevelopmental disorder originated from the gene by environment interaction which causes the limitation of inhibitory control and working memory. The estimated world pool prevalence is 5.29- 7.2%. The guidelines in the American Psychiatric Association’s Diagnostic and Statistical Manual, Fifth edition (DSM-5), currently used to help diagnose ADHD,is based primarily on history and clinical findings recorded by child’s caretaker, such as parents or teacher, and physician. Hyperactivity is the pertinent finding during childhood period which decreases and is replaced with inattentive symptoms during surpassing the adolescent period and the comorbidities are often identified. When designing plan for caring children with ADHD, child’s age, coexisting conditions, the ability of care and needs of children and their parents have to be taken into account.


Conclusions: The general principle of treatment includes medication and non-medication, such as behavioral intervention and accommodation, cooperating with appropriate monitoring. For effective treatment and achieving the maximum potential of each child, the care has to be planned specially for matching with individual needs.


Keywords: Attention deficit/hyperactivity disorder, complex ADHD, coexisting conditions

  
     
     
 
    How to Cite  
     
  มาศเกษม ก. (2020). Attention deficit/hyperactivity disorder in children and adolescence. Journal of Charoenkrung Pracharak Hospital, 16(2), 75–102. Retrieved from https://he02.tci-thaijo.org/index.php/JCP/article/view/241374  
     

 
 
     
     
 
    Issue  
     
  Vol. 16 No. 2 (2020): July - December  

 
 
     
     
 
    Section  
     
  Review  article  

 
 
     
     
     
 

References

1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164(6):942-8.
2. Thomas R, Sanders S, Doust J, Beller E, Glasziou P. Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics 2015;135(4):e994-1001.
3. NICE guideline [NG87]. Attention deficit hyperactivity disorder: diagnosis and management [Internet]. 2018 [cited 2020 Mar 15]. Available from: https://www.nice.org.uk/guidance/ng87/chapter/Context.
4. Rowland AS, Skipper BJ, Umbach DM, Rabiner DL, Campbell RA, Naftel AJ, et al. The Prevalence of ADHD in a Population-Based Sample. J Atten Disord 2015;19(9):741-54.
5. Wang T, Liu K, Li Z, Xu Y, Liu Y, Shi W, Chen L. Prevalence of attention deficit/hyperactivity disorder among children and adolescents in China: a systematic review and meta-analysis. BMC Psychiatry 2017;17(1):32.
6. ทวีศิลป์ วิษณุโยธิน, โชษิตา ภาวสุทธิไพศิฐ, พรทิพย์ วชิรดิลก, พัชรินทร์ อรุณเรือง และ ธันวรุจน์ บูรณสุขสกุล. ความชุกโรคสมาธิสั้นในประเทศไทย.วารสารสุขภาพจิตแห่งประเทศไทย 2556; 21(2): 66-75.
7. Aboul-Ata MA, Amin FA. The Prevalence of ADHD in Fayoum City (Egypt) Among School-Age Children: Depending on a DSM-5-Based Rating Scale. J Atten Disord 2018;22(2):127-33.
8. Faraone SV, Cruz LP, de la Peña Olvera FR. Understanding the essentials of the etiology of ADHD. In: Rohde LA,Buitelaar JK, Gerlach M,FaraoneSV editor(s). The World Federation of ADHD guide. Porto Alegre: ARTMED EDITORA LTDA., a GRUPO A EDUCAÇÃO S.A. company; 2019. p. 1-16.
9. Banaschewski T, Becker K, Döpfner M, Holtmann M, Rösler M, Romanos M. Attention-deficit/hyperactivity disorder—a current overview. DtschArztebl Int 2017; 114: 149–59.
10. Diamond A. Executive functions. Annu Rev Psychol 2013; 64(1): 135–68.
11. Hinshaw SP. Attention deficit hyperactivity disorder(ADHD): controversy, developmental mechanisms, and multiple levels of analysis. Annu Rev Clin Psychol 2018; 14:1.1–1.26.
12. Wolraich ML, HaganJF, AllanC, ChanE, Davison D,EarlsM, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2019; 144(4): e20192528.
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5th Eds. Arlington: American Psychiatric Publishing; 2013. p.59-66.
14. Danielson ML, Bitsko RH, Ghandour RM, Holbrook JR, Kogan MD, Blumberg SJ. Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents, 2016. J Clin Child Adolesc Psychol 2018; 47(2): 199–212.
15. Barbaresi WJ, Campbell L, Diekroger EA, Froehlich TE, Liu YH, OʼMalley E, et al. Society for Developmental and Behavioral Pediatrics Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with Complex Attention-Deficit/Hyperactivity Disorder. J Dev Behav Pediatr. 2020;41 Suppl 2S:S35-57.
16. Franke B, Michelini G, Asherson P, Banaschewski T, Bilbow A, Buitelaar JK, et al. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. Eur Neuropsychopharmacol. 2018; 28(10):1059-88.
17. Sasser TR, Kalvin CB, Bierman KL. (2016). Developmental trajectories of clinically significant attention-deficit/hyperactivity disorder (ADHD) symptoms from grade 3 through 12 in a high-risk sample: Predictors and outcomes. J Abnorm Psychol. 2016; 125(2): 207–19.
18. Caye A, Swanson J, Thapar A, Sibley M, Arseneault L, Hechtman L, et al. Life span studies of ADHD-conceptual challenges and predictors of persistence and outcome. Curr Psychiatry Rep. 2016 Dec;18(12):111.
19. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002 Feb;41(2 Suppl):26S-49S.
20. Barbaresi WJ, Campbell L, Diekroger EA, Froehlich TE, Liu YH, OʼMalley E, et al. The Society for Developmental and Behavioral Pediatrics Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with Complex Attention-Deficit/Hyperactivity Disorder: Process of Care Algorithms. J Dev Behav Pediatr. 2020;41 Suppl 2S:S58-S74.
21. Froehlich TE, Brinkman WB. Multimodal treatment of the school-aged child with attention-deficit/hyperactivity disorder. JAMA Pediatr. 2018;172(2):109-10.
22. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al. (2002). Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002; 347(5): 314–21.
23. National Institute on Alcohol Abuse and Alcoholism. Alcohol screening and brief intervention for youth, a practitioner’s guide [Internet]. 2015[cited 2020 Mar 31]. Available from: https://www.niaaa.nih.gov/sites/default/files/youth-guide.pdf.
24. Boston Children’s Hospital. Adolescent SBIRT Toolkit for Providers [Internet]. 2015[cited 2020 Mar 31]. Available from: https://www.mcpap.com/pdf/S2BI%20Toolkit.pdf
25. Jummani R, Coffey B. ADHD and tic disorders. In Adler L, Spencer T, Wilens T(Eds.), Attention-Deficit Hyperactivity Disorder in Adults and Children. Cambridge: Cambridge University Press; 2015. p. 343-352
26. Freeman RD. Tic disorders and ADHD: answers from a world-wide clinical dataset on Tourette syndrome. Eur Child Adolesc Psychiatry. 2007;16(1):15-23
27. Murphy TK, Lewin AB, Storch EA, Stock S, Bukstein OG, Walter HJ, et al. Practice parameter for the assessment and treatment of children and adolescents with tic disorders. J Am Acad Child Adolesc Psychiatry. 2013;52(12):1341-59.
28. Lanzi G, Zambrino CA, Termine C, Palestra M, Ferrari Ginevra O, Orcesi S, et al. Prevalence of tic disorders among primary school students in the city of Pavia, Italy. Arch Dis Child. 2004;89(1):45-7.
29. Yang C, Zhang L, Zhu P, Zhu C, Guo Q. The prevalence of tic disorders for children in China: A systematic review and meta-analysis. Medicine (Baltimore). 2016;95(30):e4354.
30. Children and Adults with Attention-Deficit/Hyperactivity Disorder. Medications used in the treatment of ADHD [Internet]. 2019[cited 2020 Apr 2]. Available from:
https://chadd.org/wp-content/uploads/2019/07/Medication-Chart-July-2019.pdf
31. Centers for Medicare & Medicaid Services. Stimulant and related medications: U.S. Food and Drug Administration-approved indications and dosages for use in pediatric patients [Internet]. 2015[cited 2020 Apr 2]. Available from: https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/stim-pediatric-dosingchart11-14.pdf
32. US Food & Drug Administration. Ritalin® hydrochloride(methylphenidate hydrochloride USP tablets) Ritalin-SR®(methylphenidate hydrochloride USP sustained-release tablets) [Internet]. 2013[cited 2020 Apr 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/ 010187s080,018029s049,021284s027lbl.pdf
33. US Food & Drug Administration. Ritalin LA®(methylphenidate hydrochloride)extended-release capsules [Internet]. 2010[cited 2020 Apr 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021284s018lbl.pdf
34. US Food & Drug Administration. Concerta® (methylphenidate HCl) extended-release tablets CII [Internet]. 2013[cited 2020 Apr 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021121s038lbl.pdf
35. US Food & Drug Administration. Strattera® (atomoxetine HCl) [Internet]. 2007[cited 2020 Apr 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021411s004s012s013s015s021lbl.pdf
36. US Food & Drug Administration. Adderall® CII (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets) [Internet]. 2017[cited 2020 Apr 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/011522s043lbl.pdf
37. US Food & Drug Administration. Adderall XR® (mixed salts of a single-entity amphetamine product) [Internet]. 2013[cited 2020 Apr 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf
38. US Food & Drug Administration. Kapvay® (clonidine hydrochloride) [Internet]. 2016[cited 2020 Apr 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022331s013lbl.pdf
39. Yasaei R, Saadabadi A. Clonidine. [Updated 2019 Oct 1]. In: StatPearls [Internet]. 2020[cited 2020 Apr 2]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459124/
40. US Food & Drug Administration. Intuniv® (guanfacine) [Internet]. 2013[cited 2020 Apr 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf